158 related articles for article (PubMed ID: 21422192)
41. Double site saturation mutagenesis of the human cytochrome P450 2D6 results in regioselective steroid hydroxylation.
Geier M; Braun A; Fladischer P; Stepniak P; Rudroff F; Hametner C; Mihovilovic MD; Glieder A
FEBS J; 2013 Jul; 280(13):3094-108. PubMed ID: 23552177
[TBL] [Abstract][Full Text] [Related]
42. A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6.
Klein K; Tatzel S; Raimundo S; Saussele T; Hustert E; Pleiss J; Eichelbaum M; Zanger UM
Drug Metab Dispos; 2007 Aug; 35(8):1247-50. PubMed ID: 17460029
[TBL] [Abstract][Full Text] [Related]
43. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4.
Wen B; Chen Y; Fitch WL
Drug Metab Dispos; 2009 Jul; 37(7):1557-62. PubMed ID: 19364830
[TBL] [Abstract][Full Text] [Related]
44. Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.
Mann A; Tyndale RF
Eur J Neurosci; 2010 Apr; 31(7):1185-93. PubMed ID: 20345925
[TBL] [Abstract][Full Text] [Related]
45. Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein.
Blobaum AL; Kent UM; Alworth WL; Hollenberg PF
Chem Res Toxicol; 2002 Dec; 15(12):1561-71. PubMed ID: 12482238
[TBL] [Abstract][Full Text] [Related]
46. Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy.
Bonifacio A; Keizers PH; Commandeur JN; Vermeulen NP; Robert B; Gooijer C; van der Zwan G
Biochem Biophys Res Commun; 2006 May; 343(3):772-9. PubMed ID: 16563352
[TBL] [Abstract][Full Text] [Related]
47. Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus.
Usia T; Watabe T; Kadota S; Tezuka Y
Biol Pharm Bull; 2005 Jun; 28(6):1021-4. PubMed ID: 15930738
[TBL] [Abstract][Full Text] [Related]
48. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: Evidence for complex heme interactions.
Hutzler JM; Melton RJ; Rumsey JM; Schnute ME; Locuson CW; Wienkers LC
Chem Res Toxicol; 2006 Dec; 19(12):1650-9. PubMed ID: 17173379
[TBL] [Abstract][Full Text] [Related]
50. Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane.
Chun J; Kent UM; Moss RM; Sayre LM; Hollenberg PF
Drug Metab Dispos; 2000 Aug; 28(8):905-11. PubMed ID: 10901699
[TBL] [Abstract][Full Text] [Related]
51. In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6.
Weiss J; Sawa E; Riedel KD; Haefeli WE; Mikus G
Naunyn Schmiedebergs Arch Pharmacol; 2008 Sep; 378(3):275-82. PubMed ID: 18516595
[TBL] [Abstract][Full Text] [Related]
52. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
[TBL] [Abstract][Full Text] [Related]
53. Recombinant production of human microsomal cytochrome P450 2D6 in the methylotrophic yeast Pichia pastoris.
Dietrich M; Grundmann L; Kurr K; Valinotto L; Saussele T; Schmid RD; Lange S
Chembiochem; 2005 Nov; 6(11):2014-22. PubMed ID: 16222729
[TBL] [Abstract][Full Text] [Related]
54. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation.
Projean D; Baune B; Farinotti R; Flinois JP; Beaune P; Taburet AM; Ducharme J
Drug Metab Dispos; 2003 Jun; 31(6):748-54. PubMed ID: 12756207
[TBL] [Abstract][Full Text] [Related]
55. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.
Wang A; Stout CD; Zhang Q; Johnson EF
J Biol Chem; 2015 Feb; 290(8):5092-5104. PubMed ID: 25555909
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of PDGFR tyrosine kinase activity by a series of novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides: a SAR study on the bioisosterism of pyrimidine and imidazole.
Mahboobi S; Sellmer A; Eswayah A; Elz S; Uecker A; Böhmer FD
Eur J Med Chem; 2008 Jul; 43(7):1444-53. PubMed ID: 17983688
[TBL] [Abstract][Full Text] [Related]
57. Heme oxygenase inhibition by 2-oxy-substituted 1-(1H-imidazol-1-yl)-4-phenylbutanes: effect of halogen substitution in the phenyl ring.
Roman G; Riley JG; Vlahakis JZ; Kinobe RT; Brien JF; Nakatsu K; Szarek WA
Bioorg Med Chem; 2007 May; 15(9):3225-34. PubMed ID: 17339115
[TBL] [Abstract][Full Text] [Related]
58. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
[TBL] [Abstract][Full Text] [Related]
59. In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human.
Erickson DA; Hollfelder S; Tenge J; Gohdes M; Burkhardt JJ; Krieter PA
Drug Metab Dispos; 2007 Dec; 35(12):2232-41. PubMed ID: 17881661
[TBL] [Abstract][Full Text] [Related]
60. Quantitation of human cytochrome P450 2D6 protein with immunoblot and mass spectrometry analysis.
Yu AM; Qu J; Felmlee MA; Cao J; Jiang XL
Drug Metab Dispos; 2009 Jan; 37(1):170-7. PubMed ID: 18832475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
